Methods and materials for evaluating rheumatoid arthritis

ABSTRACT

The invention provides methods and materials for diagnosing a rheumatoid arthritis condition in a patient. Specifically, the invention provides methods and materials for classifying a rheumatoid arthritis condition as diffuse, follicular, or granulomatous. In addition, the invention provides methods and materials for determining if an individual suffering from a rheumatoid arthritis condition will develop severe disease.

RELATED APPLICATIONS

This application claims priority from U.S. Provisional ApplicationSerial No. 60/098,718, filed Sep. 1, 1998.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

Support in the development of the invention described herein wasprovided by the National Institutes of Health, Grant Numbers AR42527 andAR41974, which may have certain rights in the invention.

BACKGROUND

1. Technical Field

The invention relates to methods and materials for evaluating rheumatoidarthritis as well as for determining an individual's predisposition tohave severe rheumatoid arthritis disease.

2. Background Information

Rheumatoid arthritis (RA) affects individuals in the prime of their lifeand is feared because of its potential to cause chronic pain andirreversible damage of tendons, ligaments, joints, and bones. Thesymmetrical involvement of small peripheral joints has an enormousimpact on hand and foot functions and poses therapeutic challenges thatcannot be easily overcome by joint replacement. Also, systemicmanifestations of RA are not rare and can range from relatively minorproblems, such as rheumatoid nodules, to life-threatening organ disease.

In addition, RA is a systemic inflammatory disease that primarilymanifests itself as synovial inflammation of diarthrodial joints. Thetypical histopathological changes include dense infiltration of thesynovial membrane by mononuclear cells, neoangiogenesis, and hypertrophyand hyperplasia of the synovial lining (Harris E D (ed); RheumatoidArthritis, Philadelphia, WB Saunders Co., pp.3-212 (1997); and Hale L P,Haynes B F: Pathology of rheumatoid arthritis and associated disorders.Arthritis and Allied Conditions. A textbook of Rheumatology. Edited byKoopman W J. Baltimore, Williams & Wilkins, pp.993-1016 (1997)). Theetiopathogenesis of the syndrome is not understood. Several lines ofevidence support a central role of T lymphocytes in the disease-specificpathogenic events (Todd, et al. Science, 240:1003-1009 (1988); Panayi,et al., Arthritis Rheum, 35:729-735 (1992); and Goronzy J J, Weyand C M:Rheum Dis Clin North Am, 21:655-674 (1995)). An alternative hypothesis,namely, that macrophages are the pivotal cell type in rheumatoidsynovitis, has also been proposed (Firestein G S, Zvaifler N J:Arthritis Rheum 33:768-773 (1990); and Burmester, et al., ArthritisRheum, 40:5-18 (1997)). Whether only T cells or only macrophages or bothare the causative elements in RA remains a matter of controversy(Feldmann, et al., Cell, 85:307-310 (1996); and Fox, Arthritis Rheum40:598-609 (1997)).

RA is primarily a clinical diagnosis. Symmetrical joint involvement,dominant manifestations in peripheral joints, rheumatoid factorproduction, and the formation of rheumatoid nodules are considered whenthe diagnosis is made (Arnett, et al., Arthritis Rheum. 31:315-324(1988)). The histological appearance of the synovium varies quiteextensively and the pathological findings are usually not helpful indistinguishing RA from other inflammatory arthropathies (Hale L P,Haynes B F: Pathology of rheumatoid arthritis and associated disorders.Arthritis and Allied Conditions. A textbook of Rheumatology. Edited byKoopman W J. Baltimore, Williams & Wilkins, pp.993-1016 (1997)). Inaddition, no information is available on the mechanisms underlying thetopographical arrangement of the inflammatory infiltrate in therheumatoid synovium.

Therapeutic management of RA has steadily improved over the lastdecades, mostly due to the recognition that destruction caused bychronic inflammation is irreversible and that only early and aggressiveintervention can enhance therapeutic benefit. Consequently, RA patientsare now being treated early in the disease course and disease modifyingagents are widely used. Despite these successes, major challengesremain. Presently, no curative intervention is available, side effectsof therapies are significant, and the disease may still progress whilethe patient is being treated.

SUMMARY

The invention involves methods and materials for evaluating rheumatoidarthritis in a patient. Specifically, the invention provides methods andmaterials for classifying a rheumatoid arthritis condition as diffuse,follicular, or granulomatous. In addition, the invention providesmethods and materials for determining if an individual suffering from arheumatoid arthritis condition will develop severe disease. Usefulindicators for severe disease include, without limitation, subcutaneousnodule formation (nodularity) and extra-articular involvement.

The invention is based on the discovery that the level of particularcytokines within tissue or the histological appearance of tissue or bothcan be used to classify a rheumatoid arthritis condition as diffuse,follicular, or granulomatous. This classification is important sincegranulomatous patients are more susceptible to severe rheumatoidarthritis disease. Severe rheumatoid arthritis disease can involve,without limitation, major organ involvement, which can be lifethreatening, and major joint destruction, which can be crippling. Thus,proper classification of a granulomatous rheumatoid arthritis conditioncan help provide clinicians and patients with information that can beused to determine adequate treatments.

Specifically, the invention involves analyzing a synovial tissue biopsyfor particular cytokines such as IL-4, IL-10, and IFN-γ, or forparticular histological characteristics, or both. For example, a patientcan be classified as having a diffuse condition when tissue from thatpatient contains low levels of IL-4, IL-10, and IFN-γ, or as having afollicular condition when tissue from that patient contains high levelsof IL-10 and IFN-γ and low levels of IL-4. A particular level of aparticular cytokine can be determined to be high or low based on thelevels measured from various populations. Such populations can include,without limitation, populations of patents with a diffuse condition,follicular condition, or granulomatous condition, patients withsubcutaneous nodule formation, patients with extra-articularinvolvement, patients with major joint destruction, and healthyindividuals.

The invention also is based on the discovery that patients presentingsimilar rheumatoid arthritis symptoms can have different levels ofparticular cytokines within their tissue or different histologicalappearance of their tissue. Thus, determining the tissue cytokineprofile or the histological characteristics of a synovial tissue samplefrom a patient can be used to determine the proper treatment protocol.For example, two patients having similar rheumatoid arthritis symptomsmay have different levels of IL-10 within their tissue. The patient withlow levels may benefit from a treatment of IL-I 0 while the patient withhigh levels of IL-10 may benefit from treatment with IL-10 inhibitorssuch as anti-IL-10 antibodies. Thus, determining the tissue cytokineprofile or the histological characteristics of a tissue sample from apatient can help provide clinicians and patients with information thatcan be used to determine adequate treatments.

In addition, the invention is based on the discovery that thepredisposition to develop severe disease can be determined in patientsclassified as having diffuse or follicular disease by analyzing thepatient's HLA-DRB1 alleles or frequency of CD4⁺/CD28^(null) cells orboth. Determining a patient's predisposition to develop severe diseaseis important since it allows clinicians and patients to plan and treataccordingly. Again, severe rheumatoid arthritis disease can involve,without limitation, extra-articular involvement and major jointdestruction. Moreover, analyzing a patient's HLA-DRB1 alleles and/orfrequency of CD4⁺/CD28^(null) cells can be used to determine whether apatient classified as having diffuse or follicular disease with apropensity for severe disease will have major organ damage, major jointdestruction, or both.

Specifically, the invention involves determining whether a patienthaving a diffuse or follicular condition has zero, one, or two HLA-DRB1alleles that are associated with RA and/or whether that patient has anelevated frequency of CD4⁺/CD28^(null) cells. For example, HLA-DRB1alleles that are associated with RA can be any allele having apolymorphism associated with rheumatoid arthritis including HLA-DRB1alleles that encode polypeptides having an uncharged amino acid atposition 74, no negatively charged amino acid at position 70, and apositively charged amino acid at position 71. Patients havingRA-associated polymorphisms for one or both HLA-DRB1 alleles or havingan elevated frequency of CD4⁺/CD28^(null) cells can be classified ashaving the potential to form severe disease.

In general, the invention features a method for diagnosing a rheumatoidarthritis condition in a patient. The method includes determining thelevel of a cytokine (e.g., IL-4, IL-10, and IFN-γ) within a sample fromthe patient, comparing the level of the cytokine to a reference level toobtain information about the rheumatoid arthritis condition, andclassifying the rheumatoid arthritis condition as a diffuse, follicular,or granulomatous condition based on the information. The sample can be atissue biopsy (e.g., a synovial tissue biopsy). The reference level canbe the median level of the cytokine found in tissue samples derived froma population. The population can include a population of patients havinga diffuse rheumatoid arthritis condition, a population of patientshaving a follicular rheumatoid arthritis condition, a population ofpatients having a granulomatous rheumatoid arthritis condition, apopulation of healthy individuals, a population of patients havingsubcutaneous nodules, a population of patients having extra-articularinvolvement, or a population of patients having major joint destruction.

In another embodiment, the invention features a method for determiningthe predisposition of a rheumatoid arthritis patient to develop severedisease. The method includes determining the level of a cytokine (e.g.,IL-4, IL-10, and IFN-γ) within a sample from the patient, determiningthe frequency of CD4⁺/CD28^(null) cells in the patient, comparing thelevel of the cytokine to a reference level and the frequency ofCD4⁺/CD28^(null) cells to a reference frequency to obtain informationabout the predisposition, and determining if the patient is predisposedto develop severe disease based on the information. The sample can be atissue biopsy (e.g., a synovial tissue biopsy). The reference level canbe the median level of a the cytokine found in tissue samples derivedfrom a population. The population can include a population of patientshaving a diffuse rheumatoid arthritis condition, a population ofpatients having a follicular rheumatoid arthritis condition, apopulation of patients having a granulomatous rheumatoid arthritiscondition, a population of healthy individuals, a population of patientshaving subcutaneous nodules, a population of patients havingextra-articular involvement, or a population of patients having majorjoint destruction. The frequency of CD4⁺/CD28^(null) cells can be thepercent of CD4⁺ cells that are CD28 negative. In addition, the referencefrequency can be derived from the CD4⁺/CD28^(null) cell frequency from apopulation.

Another embodiment of the invention features a method for determiningthe predisposition of a rheumatoid arthritis patient to develop severedisease. The method includes determining the level of a cytokine (e.g.,IL-4, IL-10, and IFN-γ) within a sample from the patient, comparing thelevel of the cytokine to a reference level to obtain information aboutthe rheumatoid arthritis condition, determining the presence of apolymorphism in an HLA-DRB1 allele in the patient, and determining ifthe patient is predisposed to develop severe disease based on theinformation and the presence of the polymorphism. The sample can be atissue biopsy (e.g., a synovial tissue biopsy). The reference level canbe the median level of the cytokine found in tissue samples derived froma population. The population can include a population of patients havinga diffuse rheumatoid arthritis condition, a population of patientshaving a follicular rheumatoid arthritis condition, a population ofpatients having a granulomatous rheumatoid arthritis condition, apopulation of healthy individuals, a population of patients havingsubcutaneous nodules, a population of patients having extra-articularinvolvement, or a population of patients having major joint destruction.The polymorphism can include an HLA-DRB1 allele that encodes apolypeptide having an uncharged amino acid at position 74, or anHLA-DRB1 allele that encodes a polypeptide free from negatively chargedamino acids at positions 70 and 71.

Another embodiment of the invention features a method for determiningthe predisposition of a rheumatoid arthritis patient to develop severedisease. The method includes determining the level of a cytokine withina sample from the patient, determining the frequency of CD4⁺/CD28^(null)cells in the patient, comparing the level of the cytokine to a referencelevel and the frequency of CD4⁺/CD28^(null) cells to a referencefrequency to obtain information about the rheumatoid arthritiscondition, determining the presence of a polymorphism in an HLA-DRB1allele in the patient, and determining if the patient is predisposed todevelop severe disease based on the information and the presence of thepolymorphism.

In another aspect, the invention features a kit for providing diagnosticinformation about a rheumatoid arthritis condition in a patient. The kitcontains a binding pair member and a reference chart. The binding pairmember has specific binding affinity for a cytokine such that the levelof the cytokine within a sample from the patient is determinable, andthe reference chart contains information about cytokine levels such thatan indication of the diffuse, follicular, or granulomatous nature of therheumatoid arthritis condition is determinable based on the level of thecytokine within the sample.

In another embodiment, the invention features a kit for providingdiagnostic information about a rheumatoid arthritis condition in apatient. The kit contains a binding pair member and a reference chart.The binding pair member has specific binding affinity for a nucleic acidsequence encoding a cytokine such that the level of the cytokine withina sample from the patient is determinable, and the reference chartcontains information about cytokine levels such that an indication ofthe diffuse, follicular, or granulomatous nature of the rheumatoidarthritis condition is determinable based on the level of the cytokinewithin the sample.

In another embodiment, the invention features a kit for determining thepredisposition of a rheumatoid arthritis patient to develop severedisease. The kit contains a first binding pair member, a second bindingpair member, and a reference chart. The first binding pair member hasspecific binding affinity for a cytokine or nucleic acid encoding thecytokine such that the level of the cytokine within a sample from thepatient is determinable. The second binding pair member has specificbinding affinity for a CD4⁺/CD28^(null) cell marker such that thefrequency of CD4⁺/CD28^(null) cells in the patient is determinable. Thereference chart contains information about cytokine levels andCD4⁺/CD28^(null) cell frequencies such that an indication of thepredisposition is determinable based on the level of the cytokine withinthe sample and the frequency of CD4⁺/CD28^(null) cells in the patient.

In another embodiment, the invention features a kit for determining thepredisposition of a rheumatoid arthritis patient to develop severedisease. The kit contains a binding pair member, an oligonucleotideprimer, and a reference chart. The binding pair member has specificbinding affinity for a cytokine or nucleic acid encoding the cytokinesuch that the level of the cytokine within a sample from the patient isdeterminable. The oligonucleotide primer has specific binding affinityfor at least a portion of the locus containing an HLA-DRB1 allele suchthat a polymorphism of HLA-DRB1 allele in the patient is determinable.The reference chart contains information about cytokine levels such thatan indication of the predisposition is determinable based on the levelof the cytokine within the sample and the polymorphism of the patient.The kit can contain a plurality of the oligonucleotide primers.

In another embodiment, the invention features a kit for determining thepredisposition of a rheumatoid arthritis patient to develop severedisease. The kit contains a first binding pair member, a second bindingpair member, an oligonucleotide primer, and a reference chart. The firstbinding pair member has specific binding affinity for a cytokine ornucleic acid encoding the cytokine such that the level of the cytokinewithin a sample from the patient is determinable. The second bindingpair member has specific binding affinity for a CD4⁺/CD28^(null) cellmarker such that the frequency of CD4⁺/CD28^(null) cells in the patientis determinable. The oligonucleotide primer has specific bindingaffinity for at least a portion of the locus containing an HLA-DRB1allele such that the a polymorphism of the HLA-DRB1 allele in thepatient is determinable. The reference chart contains information aboutcytokine levels and CD4⁺/CD28^(null) cell frequencies such that anindication of the predisposition is determinable based on the level ofthe cytokine within the sample, the frequency of CD4⁺/CD28^(null) cellsin the patient, and the polymorphism of the HLA-DRB1 allele.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention pertains. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein are incorporated byreference in their entirety. In case of conflict, the presentspecification, including definitions, will control. In addition, thematerials, methods, and examples are illustrative only and not intendedto be limiting.

Other features and advantages of the invention will be apparent from thefollowing detailed description, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 contains two bar graphs plotting the number of cytokinetranscripts (IFN-γ and IL-4) per β-actin transcripts for diffuse,follicular, and granulomatous synovial tissues.

FIG. 2 contains two bar graphs plotting the number of cytokinetranscripts (IL-1β and TNF-α) per β-actin transcripts for diffuse,follicular, and granulomatous synovial tissues.

FIG. 3 contains two bar graphs plotting the number of cytokinetranscripts (IL-10 and TGF-β1) per β-actin transcripts for diffuse,follicular, and granulomatous synovial tissues.

FIG. 4 contains two graphs plotting CD28 expression against CD4expression for a normal control individual (left, <1% of CD4⁺ T cellsare CD28 negative) and a RA patient (right, about 9% of CD4⁺ T cells areCD28 negative).

FIG. 5 is a bar graph depicting the correlation between the frequenciesof CD4⁺/CD28^(null) T cells and extra-articular rheumatoid arthritis.The line corresponds to the median, the box to the 25^(th) and 75^(th)percentiles, and the whiskers to the 10^(th) and 90^(th) percentiles.

FIG. 6 is a chart depicting possible genetic factors of diseaseheterogeneity in rheumatoid arthritis.

DETAILED DESCRIPTION

The invention provides methods and materials for evaluating rheumatoidarthritis in a patient. Specifically, the invention provides methods andmaterials for classifying a rheumatoid arthritis condition as diffuse,follicular, or granulomatous. In addition, the invention providesmethods and materials for determining a patient's predisposition todevelop severe rheumatoid arthritis disease.

RA can be classified as diffuse, follicular, or granulomatous based oneither the profile of cytokines produced within a synovial tissue sampleor the histological characteristics of a synovial tissue sample. Anymethod can be used to quantify specific cytokine expression withinsynovial tissue including methods that measure cytokine mRNA or cytokinepolypeptide. For example, PCR, competitive PCR, PCR-ELISA, and in situhybridization techniques can be used to measure cytokine mRNA. Inaddition, ELISA, immunohistochemistry and other immuno assays can beused to measure cytokine polypeptide. Such cytokines can be, withoutlimitation, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-12. Thehistological characteristics of a synovial tissue sample can bedetermined using common staining techniques that reveal the presence ofmacrophages and lymphocytes such as H &E staining andimmunocytochemistry.

If the cytokine profiles or histological characteristics indicate that apatient has granulomatous disease than that patient also can beclassified as being predisposed to develop a severe rheumatoid arthritiscondition including major organ involvement and major joint destructionsince granulomatous disease was discovered herein to correlate withsevere disease. If the cytokine profiles or histological characteristicsindicate that a patient has diffuse or follicular disease than furtheranalysis can be performed to determine that patient's predisposition todevelop severe disease. This further analysis can involve analyzing theHLA-DRB1 locus for alleles having polymorphisms associated with RAand/or determining the CD4⁺/CD28^(null) T cell frequency.

Determining whether a patient has zero, one, or two HLA-DRB1 allelesthat contain a polymorphism associated with RA can be accomplished usingcommonly known methods such as PCR, PCR-ELISA, and sequencing. Forexample, any method provided by the International HistocompatibilityWorkshop can be used as well as any commercially available methods ofmaterials obtained from, for example, One Lambda (Los Angles, Calif.) orBiotest Diagnostics (Denville, N.J.). Such HLA-DRB1 alleles can include,without limitation, HLA-DRB1 alleles that encode a polypeptide having anuncharged amino acid at position 74, no negatively charged amino acid atposition 70, and a positively charged amino acid at position 71.

Any method can be used to determine the frequency of CD4⁺/CD28^(null) Tcells within a patient. For example, a binding pair member havingspecificity for a marker found on CD4⁺/CD28^(null) cells can be used todetermine the frequency of those cells. Such a method can involve usingthe combination of two antibodies, one having specificity for CD4 andthe other having specificity for CD28. For example, FACS can be usedwith CD4 and CD28 specific antibodies to determine the percent of CD4⁺cells that are CD28 negative. Further, CD3 antibodies can be used todistinguish CD4⁺ T cells from CD4⁺ macrophages.

Once a frequency of CD4⁺/CD28^(null) cells in a patient is determined,that frequency can be compared to a reference frequency to obtaininformation about the patient's RA condition. Typically, a referencefrequency is derived from the CD4⁺/CD28^(null) cell frequenciesdetermined for a population of individuals. For example, a referencefrequency can be a median percent of CD4⁺ cells that are CD28 negativeas derived from a population. The population can be a population ofhealthy individuals or patients having subcutaneous nodularity,extra-articular involvement, major joint destruction, diffuse disease,follicular disease, and/or granulomatous disease. The informationobtained by this comparison can allow the patient's RA condition to beclassified as either severe or not severe. For example, if the frequencyof CD4⁺/CD28^(null) cells from a patient corresponds to the referencefrequency of CD4⁺/CD28^(null) cells derived from a population of healthyindividuals and that patient has diffuse disease and no RA-associatedHLA-DRB1 alleles, then that patient would not be classified as beingpredisposed to develop severe RA disease. Likewise, if the frequency ofCD4⁺/CD28^(null) cells from a patient corresponds to the referencefrequency of CD4⁺/CD28^(null) cells derived from a population ofpatients having subcutaneous nodularity and that patient has diffuse andno RA-associated DRB1 alleles, then that patient can be classified asbeing predisposed to develop severe RA disease. Typically, a patienthaving diffuse RA disease with greater than about 2.0% of their CD4⁺cells being CD28 negative has a predisposition to develop severe RAdisease.

A reference chart is any chart that contains information about cytokinelevels, HLA-DRB1 alleles, or CD4⁺/CD28^(null) T cell frequencies. Forexample, a reference chart can contain information about the averagefrequency of CD4⁺/CD28^(null) cells found in a particular population ofindividuals or patients. It will be appreciated that a reference chartcan be presented or contained on any type of medium (e.g., paper orelectronic formats). It is to be understood that an electronic formatcan be obtained via a software program or an accessible database site(e.g., an Internet site). For the purpose of this invention, kitscontaining a reference chart include kits having directions (e.g.,access codes or Internet address information) for accessing referencecharts in an electronic format.

A binding pair member is any molecule that specifically binds anothermolecule including, without limitation, antibodies, antibody fragmentsthat have binding specificity, ligands, nucleic acid, receptors,lectins, chelating agents, ions, and the like.

The invention will be further described in the following examples, whichdo not limit the scope of the invention described in the claims.

EXAMPLES Example 1 Three Distinct Histopathological Patterns inRheumatoid Synovitis

The pattern of cytokines produced in the rheumatoid synovium was foundto be predictive of the morphological appearance of the disease.Specifically, rheumatoid synovitis was found to be a heterogeneousentity with three distinct histologically defined phenotypes. Thephenotypic heterogeneity correlated to a specific combination of T-cell-and macrophage-derived cytokines, raising the possibility that severalpathomechanisms may cause an RA-like syndrome.

1. Study Population

Fresh synovial tissue was obtained from 21 consecutive patients withactive RA who fulfilled the American College of Rheumatology 1987revised criteria for RA (Arnett, et al., Arthritis Rheum, pp.31:315-324(1988)) and who underwent joint surgery.

2. Histopathological Evaluations

Hematoxylin and eosin sections of the tissue samples were analyzed forthe organizational structure of the inflammatory infiltrate withparticular attention to the topographical arrangement of T cells, Bcells, and macrophages as well as the degree of angiogenesis and therelationship of the mononuclear infiltrate to the subsynovial lining.All tissue samples were reviewed by a pathologist who was unaware of anyclinical, seriological, or immunohistological findings. To control forpatchiness of the inflammation and intra-specimen variation, multipleindependent specimens were included from ten patients with thepathologist blinded to the identity of the specimens. There wasconcordance for the identification of follicles and granulomatouslesions for all of the independently graded specimens.

3. Immunohistochemistry

Frozen tissue samples embedded in OCT (Miles, Elkhart, Ind.) were cutinto 5-μm sections, mounted on the gel-coated slides (Superfrost/Plus,Fisher Scientific, Pittsburgh, Pa.), and dried in a 37° C. desiccator.Slides were stored at −70° C. Before staining, slides were fixed inacetone for ten minutes, air dried, and fixed in a 1%paraformaldehyde/EDTA, pH 7.2, for three minutes. Endogenous peroxidasewas blocked with 0.3% H₂O₂ in 0.1% sodium azide. Nonspecific binding wasblocked with 5% rabbit serum (Life Technologies, Grand Island, N.Y.) for15 minutes. Sections were stained with monoclonal mouse anti-interferon(IFN)-γ Ab, 1:100 (Genzyme Diagnostics, Cambridge, Mass.) for 60 minutesor monoclonal mouse anti-CD20 Ab, 1:40 (Dako, Carpinteria, Calif.) for30 minutes at room temperature. After incubation with biotinylatedrabbit anti-mouse antibody, 1:300 (Dako), the slides were developed withstreptavidin-peroxidase, 1:250 (Dako) and 3,3′-diaminobenzidinetetrahydrochloride (Sigma Chemical Co., St. Louis, Mo.).

Slides stained with anti-IFN-γ were washed in 0.5%Triton X-100 in PBSfor ten minutes. Nonspecific binding was blocked for 15 minutes with 5%normal goat serum (Life Technologies). Sections were stained with amonoclonal mouse anti-CD45RO Ab, 1:60 (Dako), for 30 minutes at roomtemperature. After incubation with a biotinylated rabbit anti-mouseantibody, 1:300 (Dako), the slides were developed with a VectastainABC-AP kit and alkaline phosphatase substrate kit 1 (VectorLaboratories, Burlingame, Calif.). Negative controls without primary Abwere processed in parallel. Sections were counterstained withhematoxylin and permanently mounted in Cytoseal (Stephens Scientific,Riverdale, N.J.).

4. Cytokine Measurement

Total RNA was extracted from synovial tissue by using a commerciallyavailable kit (Trizol, Life Technologies). cDNA from synovial tissuespecimens was adjusted to contain equal numbers of β-actin transcripts.Adjusted cDNA was amplified under nonsaturating conditions withcytokine-specific primers (Table 1) by polymerase chain reaction (PCR)in parallel with a standard with a known number of cytokine sequences asdescribed (Weyand, et al., Arthritis Rheum, pp.40:19-26 (1997)). Primerswere chosen to amplify cDNA specifically and not genomic DNA. To achievethis goal, several primers had been designed to span an intron (Brack,et al., J Clin Invest, pp.99:2842-2850 (1997)). Amplified products werelabeled with digoxygenin-11-dUTP (Boehringer Mannheim, Indianapolis,Ind.) and then semiquantified in a liquid hybridization assay withbiotinylated internal probes (Table 1) using a commercially availablePCR ELISA kit (Boehringer Mannheim). In this assay, the labeled PCRproducts were hybridized with 200 ng/mL probe at 42° C. for β-actin,interleukin (IL)-4, IFN-γ, transforming growth factor (TGF)-β1, andtumor necrosis factor (TNF)-α and at 55° C. for IL-1β and IL-10 for twohours. Hybrids were immobilized on streptavidin-coated microtiter platesand, after washing, were detected with a peroxidase-labeledanti-digoxigenin antibody. Plates were developed by a color reactionusing ABTS (2,2′-azino-di[3-ethylbenzthiazoline sulfonate] diammoniumsalt) substrate and quantitated using a kinetic microplate reader(Molecular Devices, Sunnyvale, Calif.). The number of cytokine-specificsequences was determined by interpolation with a standard curve and wasexpressed as the number of cytokine sequences per 2×10⁶ β-actinsequences.

TABLE 1 Nucleotide Sequences of PCR Primers and Biotinylated ProbesOligonucleotide sequence β-Actin 5′ Primer ATG GCC ACG GCT GCT TCC AGC3′ Primer CAT GGT GGT GCC GCC AGA CAG Probe TAC AGG TCT TTG CGG ATG TCIL-1β 5′ Primer GAC ACA TGG GAT AAC GAG GC 3′ Primer GGG ATC TAC ACT CTCCAG CTG Probe AGC TTT TTT GCT GTG AGT CCC GGA G IL-4 5′ Primer CTT CCCCCT CTG TTC TTC CT 3′ Primer TTC CTG TCG AGC CGT TTC AG Probe AGA GCAGAA GAC TCT GTG CAC CGA G IL-10 5′ Primer CAG TTT TAC CTG GAG GAG 3′Primer CAA TAA GGT TTC TCA AGG GGC TGG GTC Probe CTA CGG CGC TGT CAT CGATTT CTT IFN-γ 5′ Primer ACC TTA AGA AAT ATT TTA ATG C 3′ Primer ACC GAATAA TTA GTC AGC TT Probe ATT TGG CTC TGC ATT ATT TTT CTG T TGF-β1 5′Primer AAG TGG ACA TCA ACG GGT TCA CTA 3′ Primer GCT GCA CTT GCA GGA GCGCAC Probe ATC TGC AAA GCT CCC GGC AC TNF-α 5′ Primer TAG CCC ATG TTG TAGCAA ACC C 3′ Primer TCG GCA AAG TCG AGA TAG TC Probe AAT GGC GTG GAG CTGAGA GAT AAC

5. Statistical Analysis

The clinical presentations of the histopathology defined patient subsetswere compared by using a Fisher's exact test. In situ cytokineproduction was compared using a nonparametric Kruskal-Wallis test.

6. Results

Microscopic evaluation of rheumatoid synovium revealed fibrin exudationand hyperplasia of synovial lining cells, often assuming a villousconfiguration, stromal fibrosis, capillary angiogenesis, and diffusestromal inflammation. Tissue-infiltrating cells included T cells,macrophages, and B cells. Giant cells were variably present. To identifypathological patterns of the synovial inflammation, a series of 21tissues from patients undergoing joint surgery was analyzed. To excludefeatures due to long standing and burned out diseases, only patientswith clinically active synovitis were enrolled.

Upon analysis by conventional histology, three patterns emerged. Tentissue samples were categorized as diffuse synovitis (Table 2). Thesetissues were characterized by a diffuse infiltrate of lymphocytes andmacrophages without any additional microanatomical arrangements. Theinfiltrate tended to be sparse and was accompanied by moderate edema aswell as delicate and diffuse fibrosis. A second pattern manifested asdemarcated lymphocytic aggregates with sparing of the interveningstroma. In some patients, indistinct germinal center formation withcentral clearing of the aggregates was apparent. Immunohistochemicalanalysis showed that follicular structures displayed a centralaccumulation of B cells surrounded by T cells. Such pseudo-follicularorganizations were detected in seven tissues and were classified asfollicular synovitis. Four patients displayed necrobiotic granulomas. Inthis pattern, a fibrinoid necrotic center was lined by a collar ofepithelioid histiocytes with or without giant cells. External to thispalisade, or garland, of histiocytes was a zone of granulation tissuewith angiogenesis and a mixed inflammatory infiltrate composed oflymphocytes, histiocytes (macrophages), and plasma cells. No specimensdisplayed both follicular synovitis and granulomatous necrobiosis.

Each specimen was evaluated further with respect to fibrinous exudates,capillary neovacularization, and linear subsynovial inflammatory arrays.These features were variable and were not correlated with each other orany of the three main inflammatory patterns.

TABLE 2 Histomorphological Characteristics of Rheumatoid SynoviumDiffuse Follicle Granuloma Patient infiltrate formation formation RA 1 +− − RA 2 + − − RA 3 + − − RA 4 + − − RA 12 + − − RA 13 + − − RA 14 + − −RA 15 + − − RA 18 + − − RA 21 + − − RA 7 + + − RA 8 + + − RA 10 + + − RA16 + + − RA 17 + + − RA 19 + + − RA 20 + + − RA 5 + − + RA 6 + − + RA9 + − + RA 11 + − +

Example 2 T-cell Derived Cytokines in Distinct Types of RheumatoidSynovitis

A semiquantitative PCR/liquid hybridization assay was used to detect lowconcentrations of cytokines in tissue extracts. To directly address thequestion of whether a correlation exists between the tissue organizationof inflammatory cells and cytokine production, the threehistomorphologically defined types of synovitis were compared for insitu transcription of the IFN-γ and IL-4 genes. To correct forvariations in the amount of tissue used for RNA extraction, all cDNAswere adjusted to a concentration equivalent to 2×10⁶ copies of theβ-actin gene product (FIG. 1). IFN-γ mRNA production was acharacteristic finding for granulomatous synovitis. Tissues withfollicular synovitis contained variable concentrations of IFN-γ mRNAcopies (median of 114 copies) whereas the lowest levels were found inextracts derived from material with diffuse synovitis (median of 55copies). As demonstrated by two-color immunohistochemistry, the majorIFN-γ producing cells in all three forms of synovitis were T cells. Thehigh rate of IFN-γ transcription distinguished patients with granulomaformation from the diffuse subtype (P=0.007).

A different pattern of tissue distribution was seen for IL-4 mRNA. IFN-γand IL-4 are both derived from T cells, but they are usually secreted bydistinct subsets of T helper cells. T cells with a commitment to theT_(H)1 pathway release IFN-γ and IL-2. Conversely, IL-4 is the typicalproduct of a T_(H)2 cell. IFN-γ and IL-4 can be considered asantagonistic effectors with IFN-γ driving inflammatory responses andIL-4 acting as an anti-inflammatory mediator. The highest concentrationof IL-4 mRNA was determined in samples with granulomatous synovitis(median of 116 copies). IL-4 transcripts were essentially absent inbiopsies from patients with follicular synovitis and were detectableonly at low levels in diffuse synovitis.

Taken together, the studies on T-cell derived cytokines indicated thatdiffuse synovitis correlated with low concentrations of IFN-γ and IL-4mRNA. This pattern might indicate a low degree of activation ofpredominantly noncommitted T_(H)0 cells. Follicular synovitis followedthe paradigm for germinal centers in that IFN-γ was the dominant T cellproduct and IL-4 was virtually absent. This type of RA would be bestdescribed as a T_(H)1 mediated response. The constellation of highlevels of IFN-γ combined with high transcription of IL-4 mRNA found ingranulomatous synovitis did not fit the current paradigm. The presenceof IL-4 mRNA was surprising and raised the question of how these twoantagonistic cytokines can co-exist in the lesions.

Example 3 Differences in Macrophage Activation Distinguish the ThreeVariants of Rheumatoid Synovitis

To address the question of whether the different organizational forms ofrheumatoid synovitis are associated with differences in the activationof synovial macrophages, the number of IL-1β and TNF-α transcripts weredetermined in the tissue extracts. IL-1β and TNF-α specific sequenceswere detected in all samples. As shown in FIG. 2, concentrations of insitu transcribed IL-1β varied extensively, ranging from 103 to 17,400copies per 2×10⁶ β-actin sequences. Low copy numbers were frequentlyfound in specimens with diffuse synovitis (median of 270 copies), andintermediate levels of IL-1β transcription were typical for follicularsynovitis (median of 2038 copies). This difference was statisticallysignificant (P=0.019). Tissue sections with granuloma formation had thehighest rate of IL-1β mRNA synthesis (median of 10,044 copies), andcould be clearly distinguished (P=0.005) from tissues with diffuseinfiltrates, which had a low level transcription. The results for TNF-αparalleled the findings for IL-1β (r²=0.860; P<0.001; FIG. 2). A lowcopy number (median of 660 copies) was found in diffusely infiltratedtissue compared with an intermediate level of TNF-α transcription infollicular tissue (median of 1799 copies; P=0.04) and highconcentrations in granulomatous synovitis (median of 9568 copies;P=0.005).

Low, intermediate, and high IL-1β and TNF-α production correlated withIFN-γ transcription in all three disease variants (r²=0.674 and P<0.001for IL-1β and r²=0.607 and P<0.001 for TNF-α compared to IFN-γ). Thisrelationship is compatible with a regulatory role of the T cell product,IFN-γ, in macrophage activation. In this model, rheumatoid granulomascould be regarded as sites of marked T cell and macrophage stimulation.The histiocyte formation characteristic of the granulomas would beconsistent with this hypothesis.

Example 4 Anti-Inflammatory Cytokines in District Variants of RheumatoidSynovitis

The concentrations of IL-10 and TGF-β1 mRNA in the tissues weresemiquantified.

IL-10 transcripts were consistently found (FIG. 3). The lowest tissueconcentration of IL-10 mRNA correlated with the presence of diffusesynovitis. In these patients, the median copy numbers of cytokine per2×10⁶ β-actin sequences was 76. In contrast, abundance of IL-10transcripts was a characteristic feature of follicular synovitis.Patients with follicular aggregates synthesized a median of 331 copiesof IL-10-specific sequences (P=0.04). Despite the marked stimulation ofmacrophages in the granulomatous synovitis, IL-10 was present at onlylow levels (median of 181 copies). Although macrophages are the mainproducer of IL-10 in the inflamed synovium, macrophage stimulation asindicated by IL-1β production can thus be differentiated from IL-10production.

TGF-β1 is understood as a powerful suppressive cytokine. To explorewhether the subdued production of T cell and macrophage products in thediffuse synovitis was correlated with a dominance of TGF-β1 mRNA, thiscytokine was analyzed in all three variants of rheumatoid synovitis.TGF-β1 sequences could easily be detected in all but one patient.Transcript concentrations ranged from 0 to 19,020 copies (FIG. 3). Lowlevels of TGF-β1 transcription was a common denominator among patientswith diffuse synovitis. They synthesized a median of 3901 copies, afinding that distinguished them from patients with follicular disease(median of 12,636 copies; P=0.025).

Therefore, neither IL-10 nor TGF-β1 could account for the abortedcytokine response in diffuse synovitis. IL-10, so far recognized as asuppressive cytokine, was transcribed in tissue samples with follicularT-B aggregates and was distinctly low in granulomatous synovitis whereasTGF-β1 mRNA was found in all three forms of synovitis.

Example 5 Host Factors Correlate with the Organization and Function ofInflammatory Cells in the Rheumatoid Synovium

Results on tissue cytokine pattern suggested that more than one type ofrheumatoid synovitis exists with distinct pathways of inflammation.Phenotypic heterogeneity of RA could be attributed to differences inhost factors. To address this issue, the three patient subsets werecompared for demographic features and for similarities in clinicalpresentation. Also, it could be argued that differences in thehistopathological appearance and functional profiles of accumulatedcells could be influenced by therapeutic intervention. Treatment givenin the last few weeks before harvesting of the tissue could beparticularly important in affecting the disease process in the synovialmembrane.

The demographic characteristics of the patient cohorts stratifiedaccording to the histomorphology of the synovitis are presented in Table3. Sex, age, and disease duration did not predict which variant ofsynovitis the patient had developed. All patients had long-standingdisease, but no differences were seen that correlated with a specificorganizational and functional pattern in the tissue. Patients lackingrheumatoid factor production accumulated among the cohort of individualsfound to have diffuse synovitis. The group of patients with diffusesynovitis included in five of ten patients who were seronegative,whereas all patients who had developed follicular synovitis secretedrheumatoid factor (P=0.04). The most intriguing finding was that thegeneration of the rheumatoid nodules was characteristic for individualswith synovial granuloma formation. All patients with granulomatoussynovitis, but none of the patients with follicular synovitis and onlyone of ten patients with diffuse synovitis, had rheumatoid nodules ofthe skin. The accumulation of patients with nodular disease in thecategory of granulomatous synovitis was statistically significant(P=0.005 versus diffuse synovitis; P=0.003 versus follicular synovitis).Pertinent treatment information is summarized in Table 4. Allindividuals with granulomatous synovitis had been treated withdisease-modifying agents (DMARDs) such as hydroxychloroquine, steroids,gold, sulphasalazine, azothioprine, and methotrexate. None of thesepatients had been managed with nonsteroidal anti-inflammatory drugs(NSAIDs) alone. The group of patients with diffuse synovitis appeared tohave been treated less aggressively. One-third of these patients wasmanaged with NSAIDs only. All patients with granuloma formation in thesynovia, but only 30 and 29%, respectively, of patients in the diffuseand follicular categories, were on methotrexate. Despite the low numberof individuals analyzed, these differences showed a trend towardsignificance (P=0.07 and P=0.06, respectively). This analysis suggestedthat host factors and/or treatment may contribute to the microanatomy inthe joint or vice versa (i.e., that a correlation exists betweensystemic manifestations and certain types of rheumatoid synovitis).

TABLE 3 Characteristics of Patient Populations Defined byHistopathological Patterns Median Rheuma- Sex Median age disease toidRheuma- (♀/ in years duration in factor toid ♂) (range) years (range)positive* nodules** Diffuse 5/5 57   16.5  50%  10% synovitis (52-73)(1-51) Follicular 6/1 57   10   100%  0% synovitis (34-67) (4-50)Granulo- 3/1 61.5  8    75% 100% matous (24-68) (5-32) synovitis *P =0.004 for diffuse versus follicular synovitis. **P = 0.005 for diffuseversus granulomatous and P = 0.003 for follicular versus granulomatoussynovitis. All other comparisons were nonsignificant.

TABLE 4 Past and Current Treatment in the Different Patient CategoriesGranulo- Diffuse Follicular matous p synovitis synovitis synovitis A vsA vs B vs (A) (B) (C) B C C NSAID only 4/10 1/7 0/4 NS NS NS (last 3months before surgery) DMARD 6/10 6/7 4/4 NS NS NS (last 3 months beforesurgery) Methotrexate 3/10 2/7 4/4 NS 0.07 0.06 (last 3 months beforesurgery) DMARD 7/10 6/7 4/4 NS NS NS (total) NSAID, nonsteroidalanti-inflammatory drugs; DMARD, disease-modifying anti-rheumatic drugs;NS, not significant.

Example 6 Tissue Cytokine Patterns Distinguish Variants of RA

RA is a chronic inflammatory disease with profound phenotypicvariability (Harris E D (ed): Rheumatoid Arthritis. Philadelphia, WBSaunders Co., pp.3-212 (1997)). The pattern of involvement, the courseand destructive potential of the disease, and the frequency ofextra-articular manifestations vary significantly. Reasons for thephenotypic heterogeneity are not completely understood but may includevariable combinations of disease risk genes (Ollier W E, MacGregor A: BrMed Bull, pp.51:267-285 (1995); and Weyand C M, Goronzy J J: Med ClinNorth Am, pp.81:29-55 (1997)). The results presented herein indicatethat the heterogeneity of the disease process includes the synoviallesion and that patients display considerable differences in theorganization and the functional commitment of the inflammatoryinfiltrates. The microanatomy of the inflamed synovium showed acorrelation with profiles of tissue cytokines, supporting the model thatdifferent mechanisms are functional in regulating rheumatoid synovitis.Tissue destruction and possible other aspects of the disease process arerelated to cell-cell interactions in the infiltrates. Thus,understanding the rules underlying the emergence of a definedmicroanatomical structure in the synovial membrane provides informationabout the fundamentally important pathological events leading up to RA.

The results from the study presented herein indicate that thetopographical arrangement of the mononuclear infiltrate can be used todefine three variants of rheumatoid synovitis. These three patternscorrelated with the combination and the amount of cytokines produced inthe tissue. In general, the level of transcription of T-cell derivedcytokines is low in synovial tissue, and the study thus employed asemiquantitative PCR approach. This technique can have limitations thatneed to be considered when interpreting the data. As it is asemiquantitative method, differences have to be large to bedistinguished. Also, the level of cytokine mRNA may not necessarilyreflect the amount of functionally active protein, particularly in thecase of TGF-β1 and IL-1β. Cytokine production was confirmed byimmunohistochemistry, which, however, is not a suitable technique todetermine quantitative differences. The finding that 21 samples weresufficient to accomplish a dissection of the three variants emphasizesthat the differences in cytokine production were pronounced.

The first variant of RA emerging from the study is a disease phenotypecharacterized by diffuse infiltrates in the synovia, a lower probabilityof rheumatoid factor production, and a clinically milder disease that isresponsive to nonaggressive treatment. The low transcription ofproinflammatory mediators of a T_(H)0 pattern suggested that the T cellresponse was not highly differentiated. Consistent with theinterpretation is the absence of a microatomical organization of themononuclear infiltrate. The reason for this subdued activation ofinflammatory cells is unclear. Production of the anti-inflammatorycytokines IL-10 and TGF-β were generally low, and no evidence was foundfor an activate suppressive mechanism.

The second variant of RA distinguished in this study represents thehistomorphological pattern that is typically associated with RA, theformation of follicular structures composed of T and B cells. Recentmolecular characterization of B cells isolated from RA tissues withfollicular centers have confirmed that these T-B cell aggregatesfunctionally resemble germinal centers (Schroeder, et al., Proc NatlAcad Sci USA, pp.93:221-225 (1996); and Randen, et al., Scan J Immunol,pp.41:481-486(1995)). Germinal centers are the site of B celldifferentiation, somatic mutation, and affinity maturation, all of whichare T-cell-dependent processes.

The tissue cytokine profile that emerged for this category includedintermediate levels of IFN-γ with essentially absent IL-4 transcription.This pattern would suggest a T_(H)1 deviation of the immune response.The predominance of a T_(H)1 pattern in patients with follicularsynovitis is in line with current knowledge in cytokine production ingerminal centers (Kelsoe G: Semin Immunol, pp.8:179-184)). Although IL-4deficient mice generated by gene targeting are not able to form lymphoidfollicles (Kuhn, et al., Science, pp.254:707-710 (1991)), T cellsaccumulating in germinal centers typically do not produce IL-4 butIFN-γ. Also the production of IL-10 found in the tissues with follicularaggregates may relate to germinal center formation (Levy Y, Brouet J C,J Clin Invest, pp.93:424-428)). IL-10 can be produced by a variety ofcells, including T_(H)1 and T_(H)2 type T-cells, macrophages, and Bcells. It acts by inhibiting the production of numerous pro-inflammatorymonokines and be attenuating T_(H)1 mediated immune responses. Incontrast to this immunosuppressive effect, IL-10 as marked stimulatoryeffects on B cells and supports B cell proliferation anddifferentiation. In particular, the production of rheumatoid factorappears to be IL-10 dependent (Perez, et al., Arthritis Rheum,pp.38:1771-1776 (1995). The data herein would suggest that theproduction of IL-10 in follicular synovitis relates to providing amicroenvironment for B cell proliferation and not for suppressingmacrophage activation.

The third variant of RA identified in this study was the least frequentand was characterized by the most abundant production of T-cell- andmacrophage-derived cytokines. From a clinical perspective, granulomatoussynovitis occurred in patients with the most serious presentation of thedisease, extra-articular RA. The morphological structures encountered inthe synovia resembled rheumatoid nodules, which are usually found in theskin (i.e., subcutaneous nodules). Unexpectedly, granulomatous andfollicular synovitis did not co-occur and follicular structures weredistinctly absent from the rheumatoid nodules. In addition, the cytokineprofiles correlating with the two histomorphologies were distinct.Granulomatous disease was characterized by high production of IFN-γ,IL-4, IL-1β, and TNF-α whereas the follicular disease resembled aclassical T_(H)1 response with the virtual absence of IL-4.

The co-production of IFN-γ and IL-4 is unusual for a granulomatousreaction. Participation of cytokines in granuloma formation has beenstudied under various experimental conditions. In general,hypersensitivity granuloma (in contrast to the nonimmuneforeign-body-type lesions) represents a chronic inflammatory infiltrateof macrophages, in particular, epithelioid macrophages, multinucleatedgiant cells and T cells (Boros D L, Prog Allergy, pp.24:183-267 (1978)).The two most widely used experimental systems are mycobacteria- andschistosoma-egg-induced granuloma formation. In these two systems,granuloma formation has been associated with quite distinct patterns oftissue cytokines. The mycobacteria-induced lesion is a characteristicT_(H)1 response, with predominantly IFN-γ at the site of inflammation(Barnes, et al., J Immunol, pp.145:149-154 (1990)). In addition toIFN-γ, TNF-α has been found to be critical in the granuloma formationduring bacile Calmette Guerin (BCG) infection (Kindler, et al., Cell,pp.56:731-740 (1989)). Because IFN-γ is known to augment TNF production,it is likely to be a critical mediator in granuloma formation. A similarcytokine pattern is seen in the chronic inflammation of giant cellarteritis, which is also characterized by granuloma formation (Weyand,et al., Ann Intern Med, pp.121:484-491(1994)). In contrast, theschistosoma-egg-induced granuloma is characterized by a T_(H)2 typeresponse with the prominent production of IL-4, IL-5, and IL-10 (Grzych,et al., J Immunol, pp.146:1322-1327 (1991); and Chensue, et al., JImmunol, pp.148:900-906(1992)). How T_(H)2 derived cytokines, inparticular IL-4, participate in this type of granuloma formation is notentirely clear. For example, it is not understood what themacrophage-activating agent in this type of lesion is. Nevertheless,T_(H)1 as well as T_(H) ² associated cytokines can apparentlyparticipate in granuloma formation.

The granuloma formation in the rheumatoid synovium was different fromthese experimental models in that IFN-γ and IL-4 were co-produced.Previous results have emphasized their antagonistic effects (Seder R A,Paul W E: Annu Rev Immunol, pp.12:635-673 (1994); Abbas, et al., Nature,pp.383:787-793 (1996); Seder, et al., J Exp Med, pp.176:1091-1098(1992); Seder, et al., Proc Natl Acad Sci USA, pp.90:10199-10192 (1993);and Szabo, et al., J Exp Med, pp.185:817-824 (1997)). Neutralization ofIFN-γ production enhances granuloma formation in the schistosoma modelalthough it abrogates the inflammation in the microbacterial model.However, it is possible that these findings are restricted to the earlystages of granuloma formation and many not apply to chronicinflammation, as is the case in the rheumatoid synovium. Indeed, atemporal participation of T_(H)1 as well T_(H) ² cells has beendescribed for the mycobacterial infection as well as for theschistosoma-egg-induced granuloma (Boros D L, Immunobiology,pp.191:441-450 (1994); Chensue, et al., J Immunol, pp.151:1391-1400(1993); and Orme, et al., J Immunol, pp.151:518-525 (1993)).

The data presented herein indicate the contribution of differentcytokines in controlling the microanatomy of the synovial inflammationand also emphasize the necessity to re-evaluate the role of the immunepathways in the pathogenesis of RA. Immune deviation is now widelyaccepted as a concept in explaining the pathogenesis of autoimmunediseases. This model implies that chronic inflammation is a consequenceof the aberrant commitment to an immune pathway in response to a givenantigen (Finkelman F D, J Exp Med, pp.182:279-282 (1995). Studies indiseases such as infection with leishmania major and mycobacteriumleprae have fueled the hypothesis that immune reactions to a givenantigen can take very different paths, and accordingly, a certain typeof disease may develop (Heinzel, et al., J Exp Med, pp.169:59-72 (1989);Yamamura, et al., Science, pp.254:277-279 (1991)). Tuberculoid leprosyand lepratomatous leprosy have been distinguished as two diseasephenotypes, the distinction being mainly attributed to the involvementof different cytokine networks. Following this model, RA has beenconsidered a consequence of an immune deviation toward a T_(H)1response, and the use of IL-4 and IL-10 have been proposed astherapeutic interventions (Heinzel, et al., J Exp Med, pp.169:59-72(1989); Yamamura, et al., Science, pp.254:277-279 (1991); Simon, et al.,Proc Natl Acad Sci USA, pp.91:8562-8566, (1994); Van Roon, et al.,Arthritis Rheum, pp.39:829-835 (1996); Isomaki, et al., Arthritis Rheum,pp.39:386-395 (1996); Walmsley, et al., Arthritis Rheum, pp.39:495-503(1996)). The present finding that RA encompasses different cytokinepatterns indicates that the choices of the host in terms of cytokinerecruitment do not determine whether or not the individual develops thedisease but can influence disease severity and organ involvement.

Alternatively, the three disease phenotypes may reflect distinctpathomechanisms including different disease initiators. As the initialevents in RA are not understood, both models remain feasible. However,searches into the instigators of RA could benefit from the realizationthat there exist several variants of the disease. It might be misleadingto search for common denominators in a cohort of RA patients if multipledistinct disease variants are represented. Focusing on a single entityof RA may enhance the identification of the shared pathomechanisms,genetic risk factors, and antigens driving rheumatoid synovitis. Equallyimportant, phenotypic variants of RA should be considered in the designof treatment trials and in the application of therapeutic agents inindividual patients.

In summary, RA is a chronic inflammatory disease with primarymanifestations in the synovial membrane. Tissue infiltrates are composedof T cells, B cells, and macrophages, but histopathological appearancesvary widely and rarely pathognomonic. Mechanisms underlying thephenotypic heterogeneity of rheumatoid arthritis are not known. Toexplore whether a correlation exists between the microscopic patterns ofrheumatoid synovitis and in situ production of cytokines, tissue samplesfrom 21 consecutive patients with clinically advanced active RA wereexamined. Based upon the organization of the lymphocyte infiltrate, thesynovial biopsies were categorized into three distinct subsets. Tensamples were characterized by diffuse lymphoid infiltrates withoutfurther microarrangements. In seven samples, lymphoid follicles withgerminal center formation were detected, and in four specimens,granuloma formation was identified. In all specimens, cytokinetranscription of interferon (IFN)-γ, interleukin (IL)-4, IL-1β, tumornecrosis factor (TNF)-α, IL-10, and transforming growth factor-β1 wassemiquantified with polymerase chain reaction and liquid phasehybridization. Each of the morphologically defined variants of synovitisdisplayed a unique cytokine profile. Low-level transcription of IFN-γ,IL-4, IL-1β, and TNF-α was typical of diffuse synovitis. In follicularsynovitis, IFN-γ was the dominant cytokine, IL-4 was virtuallyundetectable, and IL-10 was abundant. Granulomatous synovitisdemonstrated high transcription of IFN-γ, IL-4, IL-1β, and TNF-α andcould be clearly distinguished from the other phenotypes. To investigatewhether differences in the synovial lesions were related to hostfactors, patients were compared for clinical parameters. Diffusesynovitis was seen in most of the patients with seronegative RA, themildest form of the disease. In contrast, extra-articular spreading ofRA with nodule formation was typically associated with granulomatoussynovitis.

Example 7 HLA-DRB1 Alleles Associated with RA

1. The Shared Epitope Hypothesis

The association of RA to MHC class II genes was recognized in the 1970sand provided the framework for an important disease model (Rittner, etal., Mol Med 3:452 (1997)). Sharing of MHC class II alleles in RApatients was taken as evidence that the major biological function ofthese molecules, the presentation of antigenic peptides to T cells, wascritically involved in disease pathogenesis (Todd, et al., Science240:1003 (1988)). A widely accepted paradigm holds that RA representsthe sequel of pathologic T cell responses initiated and maintained byantigens presented in the context of disease-associated HLA molecules.The initial observation that the frequency of HLA-DR4 was increased inRA patients was confirmed in multiple studies and in multiple ethnicgroups. The association with HLA-DR4 was eventually attributed to someof the allelic variants of the HLA-DR4 family, including HLA-DRB1*0401,*0404, *0405, and *0408 (Table 5). Sequence similarity between thesedisease-associated alleles and the sequence differences to thenonassociated allele HLA-DRB1*0402 gave rise to the “shared epitope”hypothesis (Gregersen, et al., Arthritis Rheum 30:1205 (1987); Nepom, etal., Annu Rev Immunol 9:493 (1991); and Winchester R., Adv Immunol56:389 (1994)). This shared sequence stretch was also identified inHLA-DRB1*01 alleles enriched in Jewish patients with RA and in theHLA-DRB1*1402 allele in Yakima Indians (Willkens, et al., ArthritisRheum 34:43 (1991); and Willkens, et al., Arthritis Rheum 34:43 (1991)).The “shared epitope” hypothesis emerged as a unifying model of theHLA-DR association of RA, and it suggested a direct involvement of asequence motif spanning positions 67-74 of the HLA-DRB1 gene in thepathogenesis of RA. Numerous studies have tested the shared epitopehypothesis in patients with different ethnic backgrounds and haveprovided evidence for an over representation of a set of HLA-DRB1alleles that share sequence similarities in the third hypervariableregion of the DRB1 gene (Weyand, et al., Curr Opin Rheumatol 7:206(1995); and Winchester R., Adv Immunol 56:389 (1994). It has beenemphasized that all RA-associated alleles exhibit a preference forpositively charged amino acids at positions 70 and 71, but sequencevariations in these two positions among RA-associated alleles have beenbelieved to be of limited functional importance. Also, the role ofsequence polymorphisms at positions 67 and 74 is not understood.HLA-DRB1 *0403, which differs from the “shared epitope” alleles atposition 74, is frequently found in Hispanic patients, opening thepossibility that considerable variability is encountered in the aminoacids forming the “shared epitope.”

Resolution of the crystal structure of HLA-DR molecules has allowed forthe precise localization of the “shared epitope.” Amino acid positions70, 71, 74, and 78 have been shown to surround peptide binding pocket 4(Brown, et al., Nature 364:33 (1993); and Stem, et al., Nature 368:215(1994)). The mapping of the disease-associated sequence stretch to theantigen binding groove emphasizes a role for antigen selection, binding,and presentation in RA. Indeed, the positive charge at position 71favors the selection of peptides with a negative charge to this position(Hammer, et al., J Exp Med 181:1847 (1995)). Dessen et al. havedetermined the x-ray structure of HLA-DR4 (DRB1 *0401) complexed with ahuman type II collagen peptide (1168-1180) and have described hydrogenbonds between the Lys in position 71 of the HLA-DRβ1 chain and both themain carbonyl oxygen of the Asn and the Asp side chain at positions 4and 5 of the peptide, respectively (Dessen, et al., Immunity 7:473(1997)).

While these studies have greatly improved our understanding aboutpeptide-HLA interaction, they have also raised several questions thatremain unanswered. How likely is it that the same peptides are bound byHLA molecules that display similarities in some of the amino acidpositions in binding pocket 4, and can we indeed ignore the sequencevariations inside and outside of the shared epitope? There are notableallelic differences between RA-associated alleles that influence thebinding properties of several HLA-DR pockets, but these are notconsidered to be critical for the disease association.Disease-associated HLA-DR4 variants have either a Val or a Gly atposition 86. This dimorphism has a major impact on T cell recognition,probably by altering the specificity of peptide binding pocket 1 (Fu, etal., J Exp Med 181:915 (1991)). The collagen peptide crystallized withHLA-DRB1 *0401 has a Met in position 1 and is therefore unlikely to bindto HLA-DRB1 *0404. Also, the size of pocket 4 is smaller in DRB1 *0404/8(Arg at position 71) than in DRB1 *0401 (Lys at position 71). Sequencepolymorphisms in HLA-DR1 alleles add additional complexity. Amino acidsat position 13, which are different in HLA-DR1 and HLA-DR4, contributeto binding pocket 4. Pocket 6 is deeper in DR4 than in DR1 because ofthe smaller side chan of Val in DR4 at position 11 compared with the Leuin DR1. In contrast, a Tyr versus Ser exchange at position 30 reducesthe size of pocket 7 in DR4 in comparison with DR1. Additional differentbinding properties can be predicted for other disease-associatedHLA-DRB1 alleles, such as DRB1 *1402 and *1001.

Alternatively, models have been proposed to explain the sharing of asequence polymorphism of the HLA-DRB1 molecule in RA. Carson et al. havefavored the hypothesis that the peptide encoded by the shared epitope isrecognized as a self-antigen and may therefore influence thymicselection (Roudier, et al., Proc Natl Acad Sci USA 86:5104 (1989)).Support for this model has come from subsequent studies demonstratingthat HLA-DR-derived peptides can be presented in restriction to HLA-DQ(Salvat, et al., J Immunol 153:5321 (1994)). Albani and Carson haveshown that the recognition of microbial peptides expressing sequencehomologies to the shared epitope is altered in RA patients (Albani, etal., Immunol Today 17:466 (1996)). Based on these data, this group hasdeveloped a molecular mimicry model of RA in which positive selection inthe thymus favors T cells that cross-react between microbial andself-antigens (Albani, et al., Nat Med 1:448 (1995)). An alternativehypothesis has been proposed by David et al. who also predict a role ofHLA-DR-derived peptides in thymic selection (Taneja, et al., J ClinInvest 101:921 (1998)). They, however, have postulated that peptidesderived from non-associated HLA-DR molecules, and not fromdisease-associated molecules, are functionally important and that thesepeptides somehow select regulatory T cells that protect againstcollagen-induced arthritis.

Finally, it is possible that the shared epitope functions in RA bydirectly contacting the TCR molecule. This model has been originallyproposed based on response patterns and TCR BV gene segment usage ofalloreactive T cell clones and the mapping of antibody binding sites onthe HLA-DRβ1 chain by site-directed mutagenesis (Goronzy, et al., RheumDis Clin North Am 21:655 (1995); Hiraiwa, et al., Proc Natl Acad Sci USA87:8051 (1990); and Weyand, et al., Arthritis Rheum 37:514 (1994)). Morerecently, the crystal structure of HLA-DR peptide complexes hasconfirmed that amino acids at position 70 of the HLA-DRβ1 chain projectout of the binding site and may directly interact with the TCR (Dessen,et al., Immunity 7:473 (1997); and Stern, et al., Nature 368:215(1994)). Penzotti et al. (Arthritis Rheum 40:1316 (1997)) have modeled aTCR from an HLA-DR4-specific clone and the DRB1 *0404 molecule and havepredicted that TCR residues CDR1β Asp30, CDR2β Asn51, and CDR3β Gln97are positioned to participate in hydrostatic interactions with the DRB1residues Q and R at positions 70 and 71, respectively, of the sharedepitope. These contact residues are likely important in repertoireselection. Indeed, the RA-associated HLA-DR polymorphism has been foundto induce global repertoire changes that are reflected at the level ofTCR BV-BJ gene segment frequencies (Walser-Kuntz, et al., Immunity 2:597(1995)). In particular, TCRs were affected that had a consensusGly-Pro-Gly sequence and therefore were predicted to have a more rigidstructure.

TABLE 5 HLA-DR association of RA Cellular Disease Serotype type Genotypeassociation HLA-DR4 HLA-Dw4 HLA-DRB1 *0401 + HLA-Dw10 HLA-DRB1 *0402 −HLA-Dw13 HLA-DRB1 *0403 − HLA-DRB1 *0407 − HLA-Dw14 HLA-DRB1 *0404 +HLA-DRB1 *0408 + HLA-Dw15 HLA-DRB1 *0405 + HLA-DR1 HLA-Dw1 HLA-DRB1*0101 + HLA-DRw6 HLA-Dw9 HLA-DRB1 *1401 − HLA-Dw16 HLA-DRB1 *1402 +HLA-Dw18 HLA-DRB1 *1301 − HLA-Dw19 HLA-DRB1 *1302 −

2. The Alternative View—A “Multiple HLA Polymorphisms—Multiple DiseaseVariants” Model

The HLA-DR association of RA has been studied in many ethnic groups, andall disease-associated alleles defined so far, express the “sharedepitope.” While this observation suggests a common denominator and asingle pathomechanism underlying the HLA association of RA, severalaspects of these studies require a rethinking of such a simplifiedmodel. First, it should be noted that the strength of the association isnot uniform but varies widely depending on the ethnic background of thepatients. Second, not all shared-epitope alleles are equal, for example,HLA-DRB1*0401 may have an exceptional role.

Indications that this genetic heterogeneity may be useful in dissectingthe clinical heterogeneity of RA came from association studies inCaucasian patients stratified for different disease manifestations(Weyand, et al., Ann Intern Med 117:801 (1992); and Weyand, et al., JClin Invest 89:2033 (1992)). Earlier studies had indicated that HLA-DR4may be associated with more erosive disease (Olsen, et al., Am J Med84:257 (1988)). Subsequent studies showed that patients with rheumatoidfactor (RF)-negative (seronegative) RA were characterized by anenrichment of both the HLA-DRB1 *04 and *01 alleles (Weyand, et al., JClin Invest 95:2120 (1995)). In contrast, 90% of patients with erosiveseropositive disease had at least one copy of an HLA-DRB1 *04 allele.Sequence analysis of HLA-DRB1 *04 genes in the seronegative cohortidentified the DRB1 *0404 and B1 *0408 variants as the dominant alleles.This contrasted to the overrepresentation of B1 *0401 in theseropositive patients. Clinical dissection of the seronegative patientsdemonstrated that erosive disease occurred more frequently in theHLA-DRB1 *04-positive individuals. A similar correlation between theinheritance of HLA-DRB1 alleles and the severity of joint destructionemerged for patients with seropositive RA. While all of these patientshad erosive disease, patients carrying two disease-associated alleles,either HLA-DRB1*01/04 or HLA-DRB1*04/04, had a higher frequency of jointarthroplasty (Weyand, et al., Ann Intern Med 117:801 (1992)). Based onthese observation, it is now proposed that there is a hierarchy ofHLA-DRB1 polymorphisms determining the severity of joint inflammation.This model would imply that the disease-associated HLA-DRB1 polymorphismis not only functioning in disease initiation but also in diseaseprogression. As described herein, HLA-DRB1 typing can be used as aprognostic marker to predict disease severity.

An alternative approach would suggest that the clinical phenotypes of RAare not simply steps on a severity scale. Rather, they could be viewedas distinct entities of the disease with ultimately unique pathogeneses.Disease-associated HLA-DRB1 alleles, in spite of sharing a similarsequence stretch, may differ in their contribution to the disease. Thismodel also includes that more than one inflammatory pathway can lead tosynovitis and that the clinical category of polyarthritis is a “mixedbag” with multiple forms of inflammation. Assigning different genotypesto different types of RA also provides an explanation for the findingthat the strength of association between HLA-DR4 and disease is notmaintained in all populations. The majority of African-American patientslack HLA-DR4 (McDaniel, et al., Ann Intern Med 123:181 (1995)). Whilethis finding could raise the question whether HLA class II molecules area prerequisite in the pathological events typical for the disease, itcould also be interpreted as demonstrating fundamental differences inthe disease processes leading to symmetrical polyarthritis in Caucasiansand African-Americans. Similar considerations could be applied topopulation-based studies describing a lack of association with HLA-DR4in patients diagnosed with symmetric polyarthritis.

Some clinical observations reinforce that the different disease patternsencountered in RA may actually represent different entities. Impressivediscrepancies in the disease course of synovial inflammation andextra-articular RA are compatible with independent disease mechanisms inthese two different dimensions of RA. Major organ manifestationsfrequently occur in RA patients at times when the synovial disease isquiescent. In selected patients, rheumatoid nodules involving the skinor other organs can be induced by methotrexate although the treatmentsuccessfully controls synovial inflammation (Merrill, et al., ArthritisRheum 40:1308 (1997)). Rheumatoid nodules impress histomorphologicallyas a granulomatous reaction, distinct from the inflammatory lesions ofrheumatoid synovitis. It has, therefore, been suggested thatextra-articular disease is a different dimension of RA with differentpathomechanisms and not just a more severe form of the disease. InCaucasians, major organ involvement is essentially restricted topatients who bear HLA-DR4 and it is generally not seen in patients whoexpress only one of the other disease-associated alleles, againemphasizing the unique role of the HLA-DR4 haplotype. Even more strikingis a gene-dose effect in patients with extra-articular manifestations.Patients with erosive RF-positive joint disease are characterized by thegenotype HLA-DRB1*04/x (x represents an RA non-associated allele). Incontrast, nodule formation is a hallmark of patients with the genotypesDRB1*01/04 or DRB1*0401/0404 (Weyand, et al., J Clin Invest 89:2033(1992)). Homozygosity for DRB1*0401 is a strong predictor for rheumatoidvasculitis and Felty's syndrome (Lanchbury, et al., Hum Immunol 32:56(1991); and Weyand, et al., J Clin Invest 89:2033 (1992)) both of whichare severe complications of RA associated with significant morbidity andmortality. The importance of a gene-dose effect in extra-articulardisease does not necessarily imply an additive effect of RA-associatedHLA alleles on a severity scale. A synergistic interaction between thetwo haplotypes is a more likely scenario. In this model, the functionalrole of HLA-DRB1 alleles in synovial and extra articular disease isregarded as distinct, e.g., peptide selection in synovitis andrepertoire formation in extra-articular disease.

In summary, the diagnostic category of RA is an umbrella term thatencompasses multiple subtypes, each of which is associated withdifferent HLA-DR polymorphisms. As the heterogeneity of the diseaseshould have a major impact on disease course and therapeuticresponsiveness, HLA-DR molecules could be used to dissect the crudecategory of RA into pathogenically homogeneous subsets.

3. Patient Population and HLA-DRB1 Genotyping

The HLA-DRB1 genotype of patients classified as having a diffuse,follicular, or granulomatous phenotype was determined using PCRaccording to the methods and materials provided by One Lambda (LosAngles, Calif.) or Biotest Diagnostics (Denville, N.J.).

Example 8 Disease Phenotypes in RA and Genetic Control of T CellFunction

Additional evidence for distinct pathomechanisms in different forms ofRA has come from studies of abnormal T cell functions in RA. Severallines of evidence have implicated T cells as important players in RApathogenesis. The MHC class II association has emphasized the criticalrole of TCR-MHC interactions in the pathogenesis of the disease(Winchester R., Adv Immunol 56:389 (1994)). Equally important is thehistomorphology of rheumatoid synovitis, which points to T cells asrelevant component of pathogenic events. Inflammatory lesions in thesynovial membrane are composed of T cells, macrophages, B cells, andsynoviocytes. Notably, these inflammatory cells acquire distincttopographic arrangements of which follicular T cell-B cell aggregatesare the most interesting (Kurosaka, et al., J Exp Med 158:1191 (1983)).Follicular structures in rheumatoid synovitis display morphologic,phenotypic, and functional characteristics resembling germinal centers(Schroder, et al., Proc Natl Acad Sci USA 93:221 (1996)). The formationof germinal centers, usually restricted to lymphoid organs, is a T celldependent process and provides a unique microenvironment for thegeneration of high affinity B cell responses. Most T cell studies in RAhave therefore focused on identifying and characterizing the TCRs thatmight recognize antigen in the synovial tissue. Repertoire analysis ofsynovial T cells have demonstrated that the infiltrate is heterogeneous,that some T cells are clonally expanded, and that different T cells aredominant in different patients. These studies have emphasized theheterogeneity of the disease process without defining a commondenominator. Relatively few studies have attempted to identify variablesof T cell function that might be genetically determined and reflectdisease-risk genes. Allelic polymorphisms of TCR genes have received thegreatest attention, but these studies have remained inconclusive(Cornelis, et al., Arthritis Rheum 40:1387(1997); and Hall, et al.,Arthritis Rheum 40:1798 (1997)). More recent data, however, indicatethat abnormalities in the T cell repertoire and some unexpected T cellfunctions in RA have a genetic basis and correlate with the clinicalexpression of RA.

Several groups have made the observation that RA patients carry clonallyexpanded T cell populations not only in the synovial compartment, as onewould expect, but also in the peripheral T cell repertoire (DerSimonianH, et al., J Exp Med 177:1623 (1993); Fitzgerald J E, et al., J Immunol154:3538 (1995); Gonzalez-Quintial R, et al., J Clin Invest 97:1335(1996); Goronzy J J, et al., J Clin Invest 94:2068 (1994); Hingorani R,et al., J Immunol 156:852 (1996); and Lim A, et al., Hum Immunol 48:77(1996)). Genetic susceptibility for the formation of T celloligoclonality was suggested by the finding that CD4 T cell clones werepresent in affected as well as unaffected members of multi-case familieswith RA (Waase I, et al., Arthritis Rheum 39:904 (1996)). The isolationof clonally expanded CD4 T cells from patients with RA has allowed forthe phenotypic and functional characterization of these T cells (SchmidtD, et al., J Clin Invest 97:2027 (1996)). Expanded CD4 clonotypes werefound to be deficient for the expression of the CD28 molecule. BecauseCD28 has been identified as a key player in T cell costimulation, thisfinding raised the question whether CD28-deficient CD4 T cells arefunctionally competent and how, if so, they contribute to RA.CD28-deficient CD4 T cells, as opposed to CD8⁺/CD28^(null) T cells, areinfrequent in normal individuals. Most normal donors have <1%CD4⁺/CD28^(null) T cells (Martens P B, et al., Arthritis Rheum 40:1106(1997)). In contrast, increased frequencies of CD28-deficient CD4 Tcells are detected in patients with RA (FIG. 4). Association studies ofCD4⁺/CD28^(null) T cells in patient cohorts stratified for differentdisease manifestations showed that the size of the CD4⁺/CD28^(null) Tcell compartment is closely associated with extra-articular RA (FIG. 5).Patients with RA limited to the joint expressed a median of 1.1%CD4⁺/CD28^(null) T cells. In patients with rheumatoid nodules, 7% of theCD4 T cells were CD28-deficient. CD4 T cells lacking CD28 expressionwere encountered in almost all patients with rheumatoid organ disease.In patients with rheumatoid vasculitis, CD28-deficient T cells accountedfor up to 50% of the CD4⁺ subset. A role of CD4⁺/CD28^(null) T cells inextra-articular aspects of RA is also supported by their distributionpattern. These unusual CD4 T cells are circulating in the blood and aregenerally encountered in the synovial tissue, but they are notselectively enriched in the synovial compartment (Rittner H L, et al.,Mol Med 3:452 (1997)).

It could be argued that the emergence of CD4⁺/CD28^(null) T cells in RApatients is a consequence of chronic persistent inflammation. Severallines of evidence do not support this interpretation. In the normalpopulation, “carriers” for CD4⁺/CD28^(null) T cells can be found,although they are infrequent. In these normal individuals, as well as inRA patients, the proportion of CD4⁺/CD28^(null) T cells remains constantover several years. No influence of disease duration or therapy on theexpansion of the CD4⁺/CD28^(null) compartment has been detected. Rather,the expression of CD28-deficient CD4 T cells is a hallmark of early anduntreated disease. Most importantly, indirect evidence suggests geneticcontrol of CD4⁺/CD28^(null) T cells. A study evaluating the presence ofCD4⁺/CD28^(null) T cells in monozygotic and dizygotic twins and inspouse pairs revealed a high concordance in the monozygotic twin pairsbut a lack of correlation in the spouse pairs. It is proposed hereinthat the generation of CD4⁺/CD28^(null) T cells is at least partiallyinfluenced by inherited factors.

The molecular basis of CD28 deficiency has been addressed as the loss ofthis important costimulatory molecule and may provide clues as to howthese cells emerge. The expression of CD28 on the cell surface has beencorrelated with the presence of two DNA binding proteins that bind tosequence motifs within the minimal promoter of the CD28 gene (Vallejo AN, et al., J Biol Chem 273:8119-29 (1998)). These regulatory proteinsare absent in CD4⁺/CD28^(null) T cells, providing a tool to approach themechanisms controlling CD28 expression. So far, besides RA, one morefactor has been associated with the loss of these gene specificregulatory proteins, namely advanced age of the donor.

As outlined, the presence of CD4 T cells defective for CD28 expressioncorrelated with the presence of extra-articular disease. Available dataindicate that CD4⁺/CD28^(null) T cells differ from traditional CD4⁺helper T cells in several aspects. CD4⁺/CD28^(null) T cells aredependent on costimulatory signals provided by accessory cells to befully activated (Park W, et al., Eur J Immunol 27:1082 (1997)). However,blocking studies with CTLA-4-Ig fusion protein have demonstrated thatcostimulation does not involve a CD28/CTLA-4-CD80/CD86 interaction.Also, costimulation enhances the proliferative response and upregulatesIL-2R expression but has no effect on the cytokine production. Comparedto CD4⁺/CD28⁺ T cells, CD28-deficient CD4⁺ T cell clones produce higheramounts of IFN-γ but similar amounts of IL-2 and IL-4. IFN-γ productionis not enhanced by accessory cells, suggesting that the secretion ofIFN-γ by CD4⁺/CD28^(null) T cells is independent of costimulatorymechanisms. As a second important difference to traditional helpercells, CD4⁺/CD28^(null) T cells lack the expression of CD40 ligand(CD40L) and fail to provide helper cell signals for B celldifferentiation and immunoglobulin production (Weyand C M, et al., MechAge Develop In press (1998)). In contrast, they have been found totranscribe and produce perforin, a molecule tightly linked withcytotoxic capability (Namekawa T, et al., Arthritis Rheum.41(12):2108-16 (1998)). Cytotoxic activity of CD4⁺/CD28^(null) T cellshas been demonstrated in vitro. An inverse relationship of CD40L andperforin expression has also been shown for synovial CD4 T cells,supporting the model that synovial CD4 T cells fall into phenotypicallyand functionally distinct categories. The cytolytic capability ofCD4⁺/CD28^(null) T cells raises the question as to which target cellsare attacked by these unusual lymphocytes in vivo. This is determined bythe antigen-specificity of these expanded T cells. In vitro studies haveprovided evidence that the antigen of interest might be an autoantigenpresented by adherent cells but not by B cells (Chapman A, et al., JImmunol 157:4771 (1996); and Schmidt D, et al., J Clin Invest 97:2027(1996)). The number of antigens recognized appears to be restricted;CD28^(null) expanded clonotypes isolated from different RA patients werefound to express identical amino acid sequences in the TCR β-chain(Schmidt D, et al., Mol Med 2:608 (1996)). Because of the particularassociation of CD4⁺/CD28^(null) T cells with extra-articular disease andbecause such disease manifestations in RA have been related to vascularcomplications, it seems prudent to evaluate the interaction betweenCD4⁺/CD28^(null) T cells and endothelial cells.

In summary, patients with extra-articular RA express CD4 T cells with anunusual phenotype and an unusual functional profile. CD4⁺/CD28^(null) Tcells undergo clonal expansion in vivo, persist over many years, do nottranscribe CD40L and have cytotoxic capability (Table 6). They mayoccupy up to one-half of the CD4 compartment and are characterized bytheir ability to secrete high amounts of IFN-γ in the absence ofcostimulatory signals. The emergence of these T cells may be undergenetic control, as suggested by the high rate of concordance in thesize of the CD4⁺/CD28^(null) T cell compartment in monozygotic twins.

TABLE 6 Characteristics of CD4⁺/CD28^(null) T cells in RA OligoclonalityExpanded in early disease Persistence over years No correlation withdisease duration or therapy Infiltration into synovial lesionsCostimulation independent of CD80/CD86 Production of high concentrationsof IFN-γ Autoreactivity in response to adherent cells Impaired apoptosiswith overexpression of bcl-2 Transcriptional block of the CD28 gene dueto a deficiency of two gene-specific transcription factors

1. Cell Surface Staining to Determine CD4⁺/CD28^(null) Cell Frequency

PBMC were isolated from the patient and stained (20 minutes at 4° C.)with a combination of two of the following monoclonal antibodies,anti-CD3 (fluorescein isothiocyanate [FITC]-conjugated), anti-CD4(peridinin chlorophyll protein [PerCP]-conjugated), anti-CD8PerCP-conjugated (all from Becton Dickinson, San Jose, Calif.), andanti-CD28 FITC-conjugated (Pharmigen, San Diego, Calif.), and analyzedon a FACS Calibur flow cytometer (Becton Dickinson) to determine thefrequencies of CD3⁺CD4⁺, CD3⁺CD8⁺, and CD4⁺CD28^(null) T cells. Analysiswas performed using WinMIDI software (Joseph Trotter, Scripps ResearchInstitute, La Jolla, Calif.).

2. Flow Cytometric Analysis

Twenty thousand events were analyzed using WinMDI software. A tightlight scatter region was drawn to include only viable lymphocytes.CD3⁺CD4⁺, CD3⁺CD8⁺, CD4⁺CD28⁺, CD4⁺CD28^(null) cells were analyzed fortheir expression of the cytokines of interest. In all experiments, lessthan 1% of the cells were positive for the isotype controls,demonstrating a very high staining specificity.

Example 9 Variants of RA Defined by Distinct Patterns of SynovialInflammation

The primary manifestations of RA are found in the synovial membrane ofdiarthroidal joints. Histopathologic changes include dense infiltratesof mononuclear cells, neoangiogenesis, and hypertrophy and hyperplasiaof synoviocytes. Although it is reasonable to assume that all of thedifferent cell types accumulated in the synovial lesions have a role inthe pathologic events, the exact contributions of monocytes, T cells, Bcells, and resident synovial cells have not been delineated. Keeping inmind that more than one form of RA may exist creates the challengingquestion whether the contribution of these different cells to theinflammation may be variable. Heterogeneity of rheumatoid synovitis iscertainly encountered as far as the histomorphologic appearance of thedisease lesions is concerned. Pathologic findings in synovial tissueshave so far not been helpful in guiding clinical management. While mostother fields in medicine have used more sophisticated approaches intissue diagnostics, this has not been the case for rheumatology. RA hasremained primarily a clinical diagnosis (Arnett F C, et al., ArthritisRheum 31:315 (1988)). It is possible that the presumed lack ofinformation gained from histomorphologic inspection of synovial lesionsrelates to the misleading expectations that RA is a narrowly definedcategory that should produce a unique pathomorphology.

Evidence for heterogeneity of rheumatoid synovitis comes from the datapresented herein correlating the microanatomy of the inflamed synovialmembrane with tissue cytokine patterns. T cells, B cells, andmacrophages can acquire a highly specialized topography in the synovium.These cells usually accumulate in the sublining stroma and are eitherarranged as diffuse infiltrates or are organized into structuresreminiscent of secondary lymphoid tissues. One of the remarkablestructures found in rheumatoid synovitis is T cell-B cell aggregates,which form germinal centers (GCs). Synovial GCs include all of thenecessary cellular components and the defined topographical arrangementrequired for GC reactions to occur. Specifically, networks of CD23⁺follicular dendritic cells are localized in the centers of T cell-B cellfollicles. These networks are populated by IgD-B cells and surrounded byCD4 T cells, some of which express CD40L (Wagner U G, et al., J Immunol.161:6390-7 (1998)). The formation of GCs in the synovial membrane, aprimarily non-lymphoid tissue, is a highly significant event thatemphasizes the role of the immune system in this disease and stressesthe critical contribution of antigen and antigen recognition inpathology. It is, however, important to note that only a subset ofpatients forms such synovial GCs. Histopathologic patterns of rheumatoidsynovitis were examined in a series of biopsies collected from patientswith active arthritis (Klimiuk P A, et al., Am J Pathol 151:1311(1997)). In this case series, three distinct patterns emerged. One-thirdof all samples contained GC-like follicles. In a slightly higherproportion of samples, T cells, B cells, and CD68⁺ macrophages lacked aspecialized microanatomical formation, but formed a diffuse infiltrate.A third pattern of synovitis was encountered in the minority of samples.This granulomatous pattern was characterized by necrotic centers linedby a collar of epithelioid histiocytes, with or without giant cells.Typically, marked angiogenesis was found external to the palisade ofhistiocytes in areas with mixed infiltrates composed of lymphocytes,plasma cells, and macrophages. It is important to note that in thisstudy, follicular synovitis and granulomatous necrobiosis did notco-occur. Rather, patients appeared to either organize the synoviallesions into follicular or granulomatous patterns.

To examine the relevance of microanatomical arrangements for theinflammatory process, tissue cytokine profiles were determined. IFN-γand IL-4 were chosen as the marker cytokines for T_(H)1 and T_(H)2helper cells. IFN-γ and IL-4 were present in low abundance in tissueswith diffuse synovitis. In follicular synovitis IFN-γ was transcribed atintermediate levels but IL-4 was distinctly absent. Granulomatoussynovitis was associated with the highest tissue concentrations for bothIFN-γ and IL-4. The production of the macrophage products, IL-1β andTNF-α, correlated closely with the amount of IFN-γ mRNA. Abundanttranscription of both macrophage products was a feature of granulomatoussynovitis. Moderate levels were detected in follicular synovitis, andtissues with diffuse synovitis produced low concentrations of IL-1β andTNF-α. The subdued production of the T cell products, IFN-γ and IL-4, aswell as the macrophage products, IL-1β and TNF-α, in samples withdiffuse synovitis could not be explained by the action of theanti-inflammatory cytokines, IL-10 and TGF-β1. High transcription of theIL-10 gene was typical for follicular disease. TCF-β1 was most abundantin tissue extracts from follicular synovitis, but it was also present inhigh amounts in synovial biopsies with granuloma formation.

Taken together, reproducible patterns of organization of inflammatorycells in the synovial infiltrates were distinguished. The topography ofthe infiltrates correlated with distinct profiles of tissue cytokines,indicating that RA is not always characterized by a predominant T_(H)1response as previously reported (Simon A K, et al., Proc Natl Acad SciUSA 91:8562 (1994)) but that different cytokine pathways underlie thesynovial inflammation (Table 7). RA is not a consequence of animmunodeviation of the cellular cytokine response as has been postulatedfor other autoimmune diseases (Finkelman F D, J Exp Med 182:279 (1995)),but it includes different response patterns, each of which may begenetically determined and may have different clinical implications.

Support for clinical relevance of the described patterns in organizationand functional commitment of the infiltrating cells came from ananalysis of disease manifestations and outcome. The best predictor fordiffuse synovitis was a lack of RF production, a disease type previouslyassociated with the genotype HLA-DRB1*01 or characterized by the absenceof disease-associated HLA-DRB1 alleles. Patients with this form of RAsynovitis often only require non-steroidal anti-inflammatory drugs andinfrequently receive more aggressive treatment. Granulomatous synovitiswas encountered in patients with extra-articular spreading and noduleformation. Comparison among different joints from the same patient haveshown that a pattern is characteristic for each patient and that thesynovial lesions in different joints display identical organizations.

The phenotypic dissection of rheumatoid synovitis requires thereevaluation of the concept that has recently been proposed as the majormechanism leading to tissue destructive inflammation. Immune deviationhas been defined as an aberrant commitment to an immune pathway inresponse to a given antigen. Elegant studies in model systems such asleishmania major infection have provided evidence that, dependent on thegenetic background of the host, an immune response to a given antigencan take different directions, thereby determining whether the diseaseresolves or progresses (Heinzel F P, et al., J Exp Med 169:59 (1989)).It has been suggested that patients with RA display a similar immunedeviation with a bias towards T_(H)1 responses (Simon A K, et al., ProcNatl Acad Sci USA 91:8562 (1994)). Consequently, it has been proposed touse IL-4 and IL-10 as novel therapeutic agents in the attempt to restoreT_(H)2 responsiveness and suppress dominant T_(H)1 responses (Isomaki P,et al., Arthritis Rheum 39:386 (1996); van Roon J A, et al., ArthritisRheum 39:829 (1996); and Walmsley M, et al., Arthritis Rheum 39:495(1996)). The data herein describing three different tissue cytokineprofiles raise doubt that RA can be considered a single entity caused byoverproduction of T_(H)1 cytokines. This model may apply to only asubset of individuals clinically classified as RA. The proposedtreatment approaches with IL-4 and IL-10 illustrate the shortcomings ofa disease model of RA that does not adequately consider phenotypic andgenotypic variability. IL-4 and IL-10 might be beneficial in some butnot all forms of the disease. Ignoring the heterogeneity of the diseaseprocess and its clinical spectrum could represent a major limitation intreatment trials.

TABLE 7 Tissue cytokine patterns in subtypes of rheumatoid synovitisDiffuse Follicular Granulomatous Cytokine synovitis synovitis synovitisIFN-γ + ++ +++ IL-4 + − +++ IL-1β + ++ +++ TNF-α + ++ +++ IL-10 + +++ +TGF-β1 ++ +++ +++

Example 10 Evaluating RA

RA can be subsetted into different phenotypes that correlate with theinheritance of distinct combinations of disease-risk genes (FIG. 6).Combinations of HLA-DRB1 alleles and particular polymorphisms ofHLA-DRB1 genes are useful in dissecting patients with rheumatoid organdisease, the most feared complication of RA. Contribution from adistinct genetic system to rheumatoid organ disease is suggested by theaccumulation of unusual lymphocytes in patients suffering fromcomplications of RA. CD4 T cells characterized by the deficiency ofCD28, a major co-stimulatory molecule, expand to high frequencies inpatients with extra-articular RA. CD4⁺/CD28^(null) T cells arefunctionally active, produce high amounts of IFN-γ and use a yet unknownalternate costimulatory pathway. These cells typically undergo clonalproliferation in vivo and infiltrate into the inflammatory lesions.Concordance for the expansion of this unusual lymphocyte subset inmonozygotic twins lends support to a genetic control of their emergence.CD4⁺/CD28^(null) T cells accumulate in RA patients independent of HLA-DRpolymorphisms. Therefore, genes regulating their generation mightrepresent novel RA risk genes.

Additional RA risk genes can include genes involved in regulatingcytokine pathways. Analysis of tissue cytokine profiles in rheumatoidsynovitis demonstrated three distinct patterns of microanatomicalorganization of the inflammatory infiltrates and, more importantly, aclose correlation of lymphoid structures and cytokine networks. RA doesnot simply arise from immune deviation; at least three differentcytokine pathways are involved in RA synovitis. Recognition of thisheterogeneity is essential in trying to identify the molecularmechanisms that induce either diffuse, follicular, or granulomatoussynovitis.

Accepting the model that more than one genotype can be associated withRA has enormous implications. Genomic searches trying to identify shareddenominators among affected individuals rely heavily on the definitionof disease. If individuals with too many different types of disease arecompared, the chance of identifying disease risk genes is low. Similarconsiderations apply to studies trying to identify disease instigators.If disease processes are heterogeneous and patients with differentvariants of RA are studied, it might be impossible to identify acausative agent present in all or most of them. All of these approacheswould have a much higher power if study cohorts could be identified thatrepresented distinct disease entities. Focusing on a single variant ofRA would enhance the chance of identifying molecular abnormalities,genetic risk factors, and potential infectious agents involved in RApathogenesis. From a clinical point of view, the dissection ofphenotypic/genotypic variants of RA is critical for further explorationof new and more selective therapeutic avenues. The therapeutic benefitof intervention might depend on the ability to target the appropriatepatient subset.

The cytokine profile within synovial tissue, the patient's HLA genotype,and the patient's frequency of CD4⁺/CD28^(null) T cells was used todetermine the patient's predisposition to develop severe disease.Subcutaneous nodularity was used as an indicator of disease severity.Tissue type was independent of HLA-DRB1 genotype and CD4⁺/CD28^(null) Tcells counts were independent of HLA-DRB1 genotype (Table 8).Granulomatous disease predicts nodularity independent of HLA-DRB1genotype and CD4⁺/CD28^(null) T cells counts. With respect to diffusedisease, CD4⁺/CD28^(null) T cell counts were a better predictor fornodular disease than a HLA-DRB1 homozygous positive genotype.

TABLE 8 Evaluating RA patients for disease severity. Tissue cytokinesIL-4 low low high IL-10 low high low IFN-γ low high high Correspondingdiffuse follicular granulomatous histology Patients (number) 31 12 6RA-associated HLA- 20  7 4 DRBI *04 allele (65%) (58%) (66%) TwoRA-associated  8  3 0 HLA-DRB1 alleles (25%) (25%)  (0%) (Double-dose)Nodularity (%)  9  2 5 (29%) (17%) (84%) % of nodular patient  2  1   0%being double-dose (22%) (50%) (sensitivity) % of double-dose  2  1 N/Apatients being nodular (25%) (33%) CD4+ CD28− data  7  3 3 availableNumber of patients  3  2 2 having high CD4⁺/CD28^(null) counts Number ofpatients  2  1 3 being nodular % of patients having {fraction (2/3×)}  1100% high CD4⁺/CD28^(null) (66%) (50%) counts that are nodular

OTHER EMBODIMENTS

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

What is claimed is:
 1. A method for evaluating a rheumatoid arthritiscondition in a patient, said method comprising: a) determining the levelof one or more cytokines within a sample from said patient, wherein saidone or more cytokines is selected from the group consisting ofinterleukin-1 beta, interleukin-4, interleukin-10, interferon-gamma,tumor necrosis factor-alpha, and transforming growth factor-beta, b)comparing said level of said one or more cytokines to one or morereference levels to obtain information about said rheumatoid arthritiscondition, and c) classifying said rheumatoid arthritis condition as adiffuse, follicular, or granulomatous condition based on saidinformation.
 2. The method of claim 1, wherein said sample comprises atissue biopsy.
 3. The method of claim 2, wherein said tissue biopsycomprises a synovial tissue biopsy.
 4. The method of claim 1, whereinsaid one or more reference levels comprises information about the medianlevel of said one or more cytokines found in tissue samples.
 5. Themethod of claim 4, wherein said tissue samples are from patients havinga diffuse rheumatoid arthritis condition.
 6. The method of claim 4,wherein said tissue samples are from patients having a follicularrheumatoid arthritis condition.
 7. The method of claim 4, wherein saidtissue samples are from patients having a granulomatous rheumatoidarthritis condition.
 8. The method of claim 4, wherein said tissuesamples are from healthy individuals.
 9. The method of claim 4, whereinsaid tissue samples are from patients having subcutaneous nodules. 10.The method of claim 4, wherein said tissue samples are from patientshaving extra-articular involvement.
 11. The method of claim 4, whereinsaid tissue samples are from patients having major joint destruction.12. A kit for providing information about a rheumatoid arthritiscondition in a patient, said kit comprising: a) one or more binding pairmembers, wherein each of said one or more binding pair members hasspecific binding affinity for a cytokine such that the level of saidcytokine within a sample from said patient is determinable, wherein saidcytokine is selected from the group consisting of interleukin-1 beta,interleukin-4, interleukin-10, interferon-gamma, tumor necrosisfactor-alpha, and transforming growth factor-beta; and b) a referencechart, wherein said reference chart contains information about one ormore cytokines selected from the group consisting of interleukin-1 beta,interleukin-4, interleukin-10, interferon-gamma, tumor necrosisfactor-alpha, and transforming growth factor-beta such that anindication of the diffuse, follicular, or granulomatous nature of saidrheumatoid arthritis condition is determinable based on one or morecytokine levels within said sample.
 13. The kit of claim 12, wherein atleast one of said one or more binding pair members is an antibody. 14.The kit of claim 12, wherein said sample comprises a tissue biopsy. 15.The kit of claim 12, wherein said sample comprises a synovial tissuebiopsy.
 16. The kit of claim 12, wherein said reference chart comprisesinformation about the median level of said one or more cytokines foundin tissue samples.
 17. The kit of claim 16, wherein said tissue samplesare from patients having a diffuse rheumatoid arthritis condition. 18.The kit of claim 16, wherein said tissue samples are from patientshaving a follicular rheumatoid arthritis condition.
 19. The kit of claim16, wherein said tissue samples are from patients having a granulomatousrheumatoid arthritis condition.
 20. The kit of claim 16, wherein saidtissue samples are from healthy individuals.
 21. The kit of claim 16,wherein said tissue samples are from patients having subcutaneousnodules.
 22. The kit of claim 16, wherein said tissue samples are frompatients having extra-articular involvement.
 23. The kit of claim 16,wherein said tissue samples are from patients having major jointdestruction.
 24. A method for evaluating a rheumatoid arthritiscondition in a patient, said method comprising: a) determining the levelof one or more cytokines within a sample from said patient, wherein eachof said one or more cytokines is selected from the group consisting ofinterleukin-1 beta, interleukin-4, interleukin-10, interferon-gamma,tumor necrosis factor-alpha, and transforming growth factor-beta, b)comparing said level to one or more reference levels to obtaininformation about said rheumatoid arthritis condition, and c)classifying said rheumatoid arthritis condition as not being a diffuse,follicular, or granulomatous condition based on said information. 25.The method of claim 24, wherein said sample comprises a tissue biopsy.26. The method of claim 25, wherein said tissue biopsy comprises asynovial tissue biopsy.
 27. The method of claim 24, wherein said one ormore reference levels comprises information about the median level ofsaid one or more cytokines found in tissue samples.
 28. The method ofclaim 27, wherein said tissue samples are from patients having a diffuserheumatoid arthritis condition.
 29. The method of claim 27, wherein saidtissue samples are from patients having a follicular rheumatoidarthritis condition.
 30. The method of claim 27, wherein said tissuesamples are from patients having a granulomatous rheumatoid arthritiscondition.
 31. The method of claim 27, wherein said tissue samples arefrom healthy individuals.
 32. The method of claim 27, wherein saidtissue samples are from patients having subcutaneous nodules.
 33. Themethod of claim 27, wherein said tissue samples are from patients havingextra-articular involvement.
 34. The method of claim 27, wherein saidtissue samples are from patients having major joint destruction.